MarginsXMarginsX
Home › Markets › Health Care › HYPD

Hyperion DeFi Inc. (HYPD)

HYPD trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.47
-4.26% on the day
Market cap
$38.3M
Nano cap
Revenue · 2025
$813K
+1318.8% on 2024
Net income · 2025
-$45.3M
-5570.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1682639/000110465926036286/0001104659-26-036286-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerHYPD on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2018
SEC CIK0001682639
SEC industry codeFinance Services
Incorporated inDE

Financials · 2025

LineValue
Revenue$813K
Net income-$45.3M
Operating income-$46.7M
Net margin-5570.6%
Operating margin-5743.5%
Revenue growth+1318.8%
Cash$6.4M
Total assets$51.8M
P/E (computed)Net income was not positive
P/S (computed)47.0×

Warning signs

Cash runway
6.2 months
$6.6M cash at September 30, 2026
Share count, 1 year
+91.3%
2025-11-10 to 2026-11-09 · +2708.2% over 3 years
Going-concern doubt
No
10-Q filed November 13, 2026
Insider net buying, 12 months
$641K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"Under Accounting Standards Codification ( ASC ) Subtopic 205-40, Presentation of Financial Statements Going Concern, the Company has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet future financial obligations as they become due within one year after the date that these financial statements are issued."
10-Q 2026-11-13
Cash and burn$6.6M cash; operating cash flow -$3.2M a quarter.Report 2026-09-30
Shares outstanding15,488,133 (2026-11-09); 8,097,659 a year earlier; 44,122,225 three years earlier. 3y figure adjusted for split (1-for-80 overall).Cover page 2026-11-09
Reverse splits, 3 years1; latest 1-for-80 on 2025-02-03Source 2025-02-03
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-05-06
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorCBIZ CPAs P.C., Philadelphia, Pennsylvania, United States; changed auditors 1 time in 24 months8-K 4.01 2025-05-02
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $641K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$810K$39.6M-$1.7M$6.6M$183K$1.9M10-Q 2026-11-13
Q2 2026
2026-06-30
$358K$31.0M-$2.9M$9.6M$8.4M$1.4M10-Q 2026-08-13
Q1 2026
2026-03-31
$244K$8.8M-$4.2M$7.4M$8.5M$1.0M10-Q 2026-05-15
Q4 2025
2025-12-31
$496K-$39.8M-$4.1M$6.3M$16.1M$813K10-K 2026-03-30
Q3 2025
2025-09-30
$303K$6.6M-$2.8M$8.2M$8.3M$345K10-Q 2026-11-13
Q2 2025
2025-06-30
$0-$8.7M-$3.4M$7.5M$8.2M$44K10-Q 2026-08-13
Q1 2025
2025-03-31
$15K-$3.5M-$4.4M$3.9M$20.1M$67K10-Q 2026-05-15
Q4 2024
2024-12-31
$28K-$20.0M-$6.1M$2.1M$15.5M$57K10-K 2026-03-30

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-05-06
Latest annual report10-K2026-03-30
Latest quarterly / interim
FORM 10-Q
10-Q2026-11-13
Latest current report
FORM 8-K
8-K2026-11-12
Latest proxyDEFA14A2026-05-05

Source: SEC EDGAR submissions feed, 619 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+3.6%
1 month-23.2%
3 months-8.8%
Year to date-27.5%
1 year-48.1%
From 52-week high-48.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
BMEABiomea Fusion Inc.$0.5201-10.67%$37.8M
SERSerina Therapeutics Inc.$1.42+2.16%$37.7M
GRCEGrace Therapeutics Inc.$1.75-3.31%$36.8M
ALDXAldeyra Therapeutics Inc.$0.6696+4.01%$40.4M
CNTBConnect Biopharma Holdings Limited$0.6430-5.05%$40.5M
DWTXDogwood Therapeutics Inc.$1.06-8.62%$40.5M
ATHEAlterity Therapeutics Limited$1.960.00%$35.7M
VERUVeru Inc.$2.08-0.48%$35.5M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier